|1.||Osheroff, Neil: 17 articles (05/2014 - 01/2003)|
|2.||Felix, Carolyn A: 12 articles (03/2014 - 11/2003)|
|3.||Bailly, Christian: 10 articles (01/2016 - 04/2003)|
|4.||Ding, Jian: 10 articles (04/2015 - 08/2003)|
|5.||Bailly, C: 8 articles (02/2014 - 06/2000)|
|6.||Nitiss, John L: 8 articles (12/2012 - 01/2002)|
|7.||Miao, Ze-Hong: 7 articles (04/2015 - 08/2003)|
|8.||Guilbaud, Nicolas: 6 articles (01/2016 - 12/2008)|
|9.||Li, Tsai-Kun: 6 articles (05/2015 - 04/2003)|
|10.||Hiasa, Hiroshi: 6 articles (08/2012 - 08/2006)|
10/05/2013 - "The studies are relevant to the understanding of suppression or inhibition of DNA cleavage on formation of ternary complex with topoisomerase-II enzyme and hence the anti cancer action. "
06/01/2012 - "Previous studies by our laboratory have identified a series of 9-amino acridine compounds that block the catalytic cycle of topoisomerase II resulting in apoptosis and cell death in a variety of cancer cell lines. "
04/15/2010 - "Our study results suggest that hMOF and SIRT1 activities are critical parameters in HDACi-mediated sensitization of multidrug-resistant cancer cells to topoisomerase II inhibitor and increased H4K16 acetylation."
07/01/1999 - "As a continuation of our structure-activity relationship studies, several new 4-beta-substituted 4'-O-demethyl-4-desoxypodophyllotoxins bearing mono-, di-, or trisubstituted anilines have been synthesized and evaluated as inhibitors of DNA topoisomerase II and tumor cell growth in tissue culture. "
09/01/1995 - "Studies of topoisomerase II-mediated drug-resistance in various model systems, as well as the sequencing of such mutations from drug-resistant tumors, have shed light on the functional domains of topoisomerase II, on how it interacts with inhibitors, and on the different mechanisms by which cells avoid the toxic effects of many clinically important anti-tumor drugs."
04/01/1998 - "A number of recent studies have investigated the expression of topoisomerase II in clinical leukemia specimens. "
09/01/2015 - "Our findings demonstrate that HSPCs exposed to non-cytotoxic levels of environmental chemicals and chemotherapeutic agents are prone to topoisomerase II-mediated DNA damage at the leukemia-associated genes MLL and CBFB. "
03/01/2014 - "Similar rearrangements are seen in infant leukemias and are associated with gestational diets that are high in naturally occurring topoisomerase II-active compounds. "
03/01/2014 - "Topoisomerase II and leukemia."
01/20/2013 - "Previous reports have revealed that the two drugs are topoisomerase II catalytic inhibitors, and patients treated with these agents have developed unique types of secondary leukemia. "
|3.||Breast Neoplasms (Breast Cancer)
02/01/2011 - "Our data do not support a correlation between topoisomerase II-α expression in breast cancer patients and improved clinical benefit with anthracycline therapy. "
02/01/2011 - "The objective of this study was to evaluate if topoisomerase II-α overexpression predicts response to anthracycline treatment in locally advanced breast cancer patients. "
03/01/2014 - "Expression of topoisomerase II-α in triple negative breast cancer."
01/01/2014 - "Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer."
11/15/2012 - "BRCA1-competent breast cancer cell lines exhibited different responses to topoisomerase II inhibition. "
02/13/2003 - "From this study, we have identified two FQAs with sharply contrasting profiles of potent G-quadruplex interaction with a weak topoisomerase II poisoning effect, and vice versa, for further evaluation to determine the optimum combination of these activities in subsequent in vivo studies."
06/01/2001 - "The present study on topoisomerase II poisoning by these two compounds opens a new avenue for renewing further research on these compounds. "
10/01/2014 - "The precise definition of the structural requirements for effective topoisomerase II poisoning by drug molecules is still an elusive issue. "
01/01/2013 - "Our results showed that QNT11 as a fluoroquinolone derivative exerted potent and selectively anticancer activity through the mechanism of eukaryotic topoisomerase II poisoning. "
01/01/2011 - "Inhibition or poisoning of maternal topoisomerase II delays embryonic development by extending the cell cycle M-phase. "
|5.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
04/01/2013 - "Topoisomerase II (TopoII) plays a critical role in the processes of replication, transcription, and decantenation in the cell and is an important chemotherapeutic target in the treatment of small cell lung cancer (SCLC). "
05/01/1997 - "Topoisomerase II levels and drug response in small cell lung cancer."
11/01/1994 - "Differential sensitivity patterns in small cell lung cancer cell lines: detection and circumvention of resistance to topoisomerase II targeting drugs."
01/01/1994 - "Low frequent doses theoretically inhibit topoisomerase II activity over a longer duration and have been reported to have increased activity in small-cell lung cancer. "
11/18/1992 - "Characterization of a topoisomerase II gene rearrangement in a human small-cell lung cancer cell line."
|1.||Etoposide (VP 16)
|2.||Type I DNA Topoisomerases (Topoisomerase I)
|3.||DNA (Deoxyribonucleic Acid)
|5.||trioctyl phosphine oxide (TOPO)
|7.||DNA topoisomerase II alpha
|9.||Teniposide (VM 26)
|10.||Messenger RNA (mRNA)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)